FDA Approval of Isatuximab in 1L MM: Perspectives for Practice

Dana-Farber Cancer Institute

P. Richardson

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Louisville Hematology Highlights

R. Gale

Multiple Myeloma: A Journey From Pharaoh's Times to 2024

Houston Methodist

S. Ganguly

Multiple Myeloma: Not as Simple as "CRAB" Anymore

Fred Hutch 14th Annual Comprehensive Hematology & Oncology Review Course

R. Banerjee

2024 Updates on Emerging & Current Treatment of Multiple Myeloma

Indy Hematology Review

K. Anderson

ESMO 2024 Summary: Highlights in Heme Malignancies

2024 ESMO Annual Meeting Insights Hub

M. Gomes da Silva

ASCO® 2024 Summary: "The Best of Myeloma - Review of the Top 5 Abstr…

2024 ASCO® Annual Meeting Insights Hub

H. Hashmi

Advances in Multiple Myeloma 2024: From Bench to Bedside

Dana-Farber Cancer Institute

K. Anderson

CARTITUDE-4 Update: OS With Cilta-Cel vs. SOC in Len-Refractory Mult…

Maria-Victoria Mateos

Anti-BMCA Bispecific Antibodies - Independent Symposium at the 10th …

Springer Healthcare IME

S. Usmani

When to Consider Bispecific and CAR-T Therapy in MM

SOHO Brazil 2024

N. S. Raje

Multiple Myeloma: Hot Topics in 2024

Yale Cancer Center

S. Browning

Cellular Therapy in 2024: What, Why, When, Who… and Where Are We Goi…

University of Colorado Department of Medicine

J. Gutman

Treatment Strategies for R/R MM After Frontline Anti-CD38 Therapy

Integrity CE

S. Usmani, J. Hillengass

Will CAR-Ts and Bispecifics Replace HSCT in Myeloma?

MyCancerHaven

R. Vij, S. Al Hadidi

Managing Newly Diagnosed MM in 2024

Indy Hematology Review

S. Usmani

The Relapsed and Refractory MM Patient: When Immune Approaches Are I…

Joseph Mikhael

Indefinite Treatment of Multiple Myeloma: Strategies for Frail Patie…

Shaji Kumar

ASCO® 2024 Summary: "Quadruplets in NDMM - The More the Better?"

2024 ASCO® Annual Meeting Insights Hub

O. Landgren

Highlights of Recent Updates in Myeloma: Part 1 - Frontline Treatment

2024 ASCO® Annual Meeting Insights Hub

A. Jakubowiak